The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Anatomy of Medical Research: US and International Comparisons
Abstract
IMPORTANCE: Medical research is a prerequisite of clinical advances, while health service research supports improved delivery, access, and cost. Few previous analyses have compared the United States with other developed countries. OBJECTIVES: To quantify total public and private investment and personnel (economic inputs) and to evaluate resulting patents, publications, drug and device approvals, and value created (economic outputs). EVIDENCE REVIEW: Publicly available data from 1994 to 2012 were compiled showing trends in US and international research funding, productivity, and disease burden by source and industry type. Patents and publications (1981-2011) were evaluated using citation rates and impact factors. FINDINGS: (1) Reduced science investment: Total US funding increased 6% per year (1994-2004), but rate of growth declined to 0.8% per year (2004-2012), reaching $117 billion (4.5%) of total health care expenditures. Private sources increased from 46% (1994) to 58% (2012). Industry reduced early-stage research, favoring medical devices, bioengineered drugs, and late-stage clinical trials, particularly for cancer and rare diseases. National Insitutes of Health allocations correlate imperfectly with disease burden, with cancer and HIV/AIDS receiving disproportionate support. (2) Underfunding of service innovation: Health services research receives $5.0 billion (0.3% of total health care expenditures) or only 1/20th of science funding. Private insurers ranked last (0.04% of revenue) and health systems 19th (0.1% of revenue) among 22 industries in their investment in innovation. An increment of $8 billion to $15 billion yearly would occur if service firms were to reach median research and development funding. (3) Globalization: US government research funding declined from 57% (2004) to 50% (2012) of the global total, as did that of US companies (50% to 41%), with the total US (public plus private) share of global research funding declining from 57% to 44%. Asia, particularly China, tripled investment from $2.6 billion (2004) to $9.7 billion (2012) preferentially for education and personnel. The US share of life science patents declined from 57% (1981) to 51% (2011), as did those considered most valuable, from 73% (1981) to 59% (2011). CONCLUSIONS AND RELEVANCE: New investment is required if the clinical value of past scientific discoveries and opportunities to improve care are to be fully realized. Sources could include repatriation of foreign capital, new innovation bonds, administrative savings, patent pools, and public-private risk sharing collaborations. Given international trends, the United States will relinquish its historical international lead in the next decade unless such measures are undertaken.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given these demands, many RCTs are conducted with substantial industry funding, and the pharmaceutical industry remains one of the main sponsors of health research (Flacco et al. 2015; Moses et al. 2015; Holman and Elliott 2018).”
From Sponsorship bias in randomised controlled trials on postoperative pain after third molar extraction: A meta-research study (2026) · cites this paper as Moses et al. 2015
In the citing paper
“Also, many research projects in the USA are funded by private initiatives, unlike most other countries 29 , 30 , 31 .”
From Global mapping of randomized controlled trials in dentistry (2024) · cites this paper as [31]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [26]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [26]
Citations
Cites
The lever of riches: technological creativity and economic progress
(1990) · Choice Reviews Online · doi:10.5860/choice.28-1056 · Cited by 1,900
The Handbook of Organizational Economics
Gibbons, R. S., & Roberts, J. (2012) · Princeton University Press eBooks · doi:10.1515/9781400845354 · Cited by 720
Introduction of surgical safety checklists in Ontario, Canada
Urbach, D. R., Govindarajan, A., Saskin, R., Wilton, A. S., & Baxter, N. N. (2014) · New England Journal of Medicine · doi:10.1056/nejmsa1308261 · Cited by 627
The Wealth of Knowledge: Intellectual Capital and the Twenty-first Century Organization
Stewart, T. A. (2001) · Medical Entomology and Zoology · Cited by 526
The Relation between Funding by the National Institutes of Health and the Burden of Disease
Gross, C. P., Anderson, G. F., & Powe, N. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402406 · Cited by 509
Financial Anatomy of Biomedical Research
Moses, H., Dorsey, E. R., Matheson, D. H. M., & Thier, S. O. (2005) · JAMA · doi:10.1001/jama.294.11.1333 · Cited by 448
Self-citationFunding of US Biomedical Research, 2003-2008
Dorsey, E. R. (2010) · JAMA · doi:10.1001/jama.2009.1987 · Cited by 337
Self-citationThe Anatomy of Health Care in the United States
Moses, H., Matheson, D. H. M., Dorsey, E. R., George, B. P., Sadoff, D., & Yoshimura, S. (2013) · JAMA · doi:10.1001/jama.2013.281425 · Cited by 328
Self-citationCryer, L., Shannon, S. B., Amsterdam, M. V., & Leff, B. A. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1132 · Cited by 282
NIH Disease Funding Levels and Burden of Disease
Gillum, L. A., Gouveia, C., Dorsey, E. R., Pletcher, M., Mathers, C. D., McCulloch, C. E., & Johnston, S. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016837 · Cited by 248
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–447 of 447
Do governments give diabetes the attention it deserves?
Speight, J., & Holmes‐Truscott, E. (2023) · Diabetic Medicine · doi:10.1111/dme.15186
Enhancing medical field with e-health and AI: A systematic review
Rai, R., Vats, R., Vermas, G., & Kumar, M. (2023) · AIP conference proceedings · doi:10.1063/5.0153923
Trauma systems on the battlefield
Remick, K. N., Bradley, M. J., Jessie, E., Malone, D. L., Elster, E. A., Gurney, J. M., Shackelford, S. A., & Bailey, J. A. (2023) · Current Therapy of Trauma and Surgical Critical Care · doi:10.1016/b978-0-323-69787-3.00020-4
Toy, K. A., Titter, J., Clark, P., Sanders, J., & Hart, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91259-4.00003-5
Information on medicines: Does independence from industry influence matter?
Mintzes, B. J. (2024) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v16i1.4522
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13829-4.00015-5
Pediatric Type 1 Diabetes: A Bibliometric Analysis of the 100 Most-cited Publications
Dayal, D., Gupta, B. M., Mamdapur, G. M. N., Vaishya, R., Gupta, A., & Bansal, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_77_24
Nanoparticles for the Treatment of Ischemic Heart Diseases
Mohamed, N. A., Benslimane, F. M., & Zakaria, Z. Z. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837671113-00047
Mod større gennemsigtighed: Ugeskrift for Læger styrker fokus på interessekonflikter
Fally, M., Hansen, B. H., & Benfield, T. (2024) · Ugeskrift for Læger · doi:10.61409/v205201
Padmanabhan, S., McLaughlin, R., & Dominiczak, A. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95311-5.00002-6
A Proposed Component of an Extubation Readiness Bundle: Science or Marketing?
Cheifetz, I. M. (2025) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000003802
Wang, T. T., Liang, L., Lee, K. C., & Lee, C. (2025) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2025.08.007
Breaking the gatekeepers: how AI will revolutionize scientific funding
Mangalam, M. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1667752
Efficacy of Stem Cell Therapy in Non-Malignant Untreatable Pediatric Diseases: An Update
Sadat‐Ali, M. (2025) · Open Journal of Pediatrics · doi:10.4236/ojped.2025.155071
Proposed Cuts to Health Research Threaten the Future of Drug Discovery and Development
Heppner, D. E. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02080
Verastegui, A., Gómez-Gutiérrez, O. A., Huerta, L. P., Castaneda, R., & Fabiani, M. A. (2025) · Scientometrics · doi:10.1007/s11192-025-05423-x
Yan, Z. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009381338.015
Dhillon, P., Saway, B. F., Galimba, A., Stegmann, K. P., Nawabi, N. L. A., Lü, Y., Saigal, R., Margetis, K. D., Fehlings, M. G., & Wilson, J. R. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.10.030
Disease Mongering: Corporate Greed and the Creation of Disease
Lexchin, J., Fugh‐Berman, A., & Mintzes, B. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00033-4
The 100 Top-cited Articles on Cervical Spine Surgery
Ezzat, B., Sabo, G. C., Asfaw, Z. K., Lemonick, M. B., Bhanot, P., Habib, J., Carr, M. T., Schüpper, A. J., & Choudhri, T. F. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001994
Mahmood, H., Deshwal, A., Khalid, A., & Mc Manus, E. (2024) · Figshare · doi:10.6084/m9.figshare.26943765
Mahmood, H., Deshwal, A., Khalid, A., & Mc Manus, E. (2024) · Figshare · doi:10.6084/m9.figshare.26943771
Mahmood, H., Deshwal, A., Khalid, A., & Mc Manus, E. (2024) · Figshare · doi:10.6084/m9.figshare.26943768
Nimgaonkar, A., Mughal, A. Y., Heimer, H., Nimgaonkar, V., Greenstein, D., & Wright, A. (2022) · Figshare · doi:10.6084/m9.figshare.20003586
Shalev, L., Helfrich, C. D., Ellen, M., Avirame, K., Eitan, R., & Rose, A. J. (2023) · Figshare · doi:10.6084/m9.figshare.24636470
Réinventer l'intégrité académique à l'ère de l'intelligence artificielle
Szecel, D., Melvin, T., & Oosterlinck, W. (2025) · doi:10.3917/ems.berga.2025.01.0125
Mao, M., Zhu, J., Cai, G., & Meng, J. (2026) · Medicine · doi:10.1097/md.0000000000046814
“[41,42] The integration of immunological biomarkers into clinical workflows represents a key advancement in personalized transplant medicine, enabling risk-adapted interventions and improved patient outcomes.”
Practical research ethics for the private practice physician: From principle to procedure
Lopez, A. M., Lehman, B., & Oh, M. Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13750-1.00024-0
Ni, J., Xu, P., & Lu, W. (2026) · International Journal of COPD · doi:10.2147/copd.s563591
Exploring research trends in decreased sound tolerance: A preliminary scientometric review
Malik, M. R., Kumar, K., Hegde, S., Ravi, R., Gunjawate, D. R., & Kalaiah, M. K. (2026) · Acta Psychologica · doi:10.1016/j.actpsy.2026.106669
Telling the good story: supporting children's first 1,000 days in Northwest Tasmania
Hills, A. P., Burgess, K., Jayasinghe, S. U., Nailon, D., Mulcahy, K., & Byrne, N. M. (2026) · International Journal of Qualitative Studies on Health and Well-Being · doi:10.1080/17482631.2026.2654064
Ariey-Bonnet, J. (2020) · theses.fr (ABES) · doi:10.70675/63ceaea1ze673z40c3z9960zed4c40d88ea9
The increasing role of venture capital in novel drug discovery
Duey, M., & Duey, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00095-9
Longitudinal Evaluation of Research Career Intentions Among US Medical Students
Hajduk, A. M., O’Connell, M., Aviles, A., Herrin, J. S., Nguyen, M., Venkataraman, S., White, M. A., Sánchez, J. P., Wolfson, R. K., Boatright, D. B., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.11430
Shalev, L., Lubin, G., Kirresh, S., Barash, I., Tamari-Guterman, A., Bloemhof‐Bris, E., Hirschmann, S., Avni, A., Avirame, K., Linder, M., et al. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1810008
“When a change or innovation is introduced in a new setting, understanding enablers and barriers to the change is crucial to determining why interventions succeed or fail (38, 39).”
Беляева, И. Н., Shemetova, G., Полиданов, М., Rastyagaeva, D. A., Шачиков, Н., Morev, D. S., Шебзухова, А., Травина, Д., Разыгрина, Т., Шихбабаева, А., et al. (2026) · CyberLeninK (CyberLeninka) · doi:10.60797/irj.2026.167.20
Academia and industry in the age of artificial intelligence: a narrative review
Bernstam, E. V., Johnson, T. R., & Alahdab, F. (2026) · BMJ Digital Health & AI · doi:10.1136/bmjdh-2026-000047
“8 Once a drug is approved, industry handles manufacturing, marketing and distribution, WHAT IS ALREADY KNOWN ON THIS TOPIC ⇒ We are currently experiencing an artificial intelligence (AI) boom that promises to revolutionise many domains, including the traditional activities of academic medical…”
Lexchin, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-27479-3_3
Huang, X., chen, Q., & Lü, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1856373
“…fi nancial investments in biomedicine in the United States, where high-cost investments facilitate the production of high-quality research outcomes (29); b) the concentration of world-class universities and research institutions, which fosters innovation; c) a powerful biomedical industry that…”
Medical Societies in the United States: History, Purpose, Challenge, and Future Directions
Schiller, G. J., & Leer, L. R. (2026) · Cureus · doi:10.7759/cureus.112407
“Declining federal funding, bureaucratic complexity, and inequities in research opportunities necessitate that medical societies serve as advocates and incubators for young investigators [10].”
Brewer, C. F., Chase, T. J. G., & Donnely, E. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01015-w
Uncovering research themes in coronary slow flow predictors: a bibliometric and cluster analysis
Liu, D., Chen, Y., Zhong, T., & Zhang, Y. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-04638-0
“Furthermore, journals were categorized based on their Journal Citation Reports (JCR) impact factors (IF) [15], which serve as a metric of a journal’s influence by averaging the number of citations received by its articles.”
Integrative biosystems: Unlocking the future of precision medicine
Akbar, A., Aziz, M., Qayyum, R., Shah, A., Salma, U., Ullah, K., & Khan, S. U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44091-5.00021-2
Mentorship as Academic Altruism Building Inclusive and Sustainable Scholarly Communities
Pareek, K. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-8480-1.ch003
We are not Denmark: Why Their Childhood Immunization Program Does not Apply to us
Weisleder, P. (2026) · Journal of Child Neurology · doi:10.1177/08830738261488631
Home Sleep Apnea Testing Over 25 Years: A Bibliometric Analysis of Global Research Trends
Marcotte, M., Lee, M. S., Chen, T., Nguyen, L. H., & Gurberg, J. (2026) · Cureus · doi:10.7759/cureus.117063
Metadata
- Authors
- Moses, H., Matheson, D. H. M., Cairns-Smith, S., George, B. P., Palisch, C., & Dorsey, E. R.
- Affiliations
- Johns Hopkins University (US)
- Boston Consulting Group (United States) (US)
- Boston Consulting Group, Boston, Massachusetts
- University of Rochester Medicine (US)
- Stanford Medicine (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-01-13
- Volume
- 313
- Issue
- 2
- Pages
- 174
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2099877908
- Cited by
- 446
- References
- 34
- Citations by year
- 2026: 21 · 2025: 37 · 2024: 24 · 2023: 32 · 2022: 30 · 2021: 40 · 2020: 37 · 2019: 36 · 2018: 47 · 2017: 46 · 2016: 56 · 2015: 39
- FWCI
- 67.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Research, Science, and Academia
- Keywords
- health research funding, research investment, health services research, research productivity, National Institutes of Health, globalization of science, health care expenditure, rare diseases, cancer research, HIV/AIDS research, citation counts, impact factor, health system innovation
- MeSH terms
- Clinical Trials as Topic, Efficiency, Health Expenditures, Health Services Research, Industry, National Institutes of Health (U.S.), Patents as Topic, Publishing, Research Support as Topic, United States, Private Sector, Drug Approval, Device Approval, Biomedical Research, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
